Volume 27, Number 5—May 2021
Research
Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands
Table 5
RDT result | Culture result | PCR Ct |
Total | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<20 |
20–25 |
25–30 |
>30 |
||||||||||
No. | Median days after onset (range)† | No. | Median days after onset (range)‡ | No. | Median days after onset (range)§ | No. | Median days after onset (range)¶ | ||||||
+ | NA | 1 | 2 | 4 | 3.5 | 4 | 6.5 | 0 | NA | 9 | |||
+ | + | 30 | 3 | 74 | 4 | 30 | 4 | 1 | 9 | 135 | |||
+ | − | 0 | NA | 3 | 5 | 4 | 5.5 | 7 | 7 | 14 | |||
− | NA | 0 | NA | 0 | NA | 1 | 3 | 0 | NA | 1 | |||
− | + | 0 | NA | 1 | 7 | 4 | 5.5 | 0 | NA | 5 | |||
− |
− |
0 |
NA |
0 |
NA |
3 |
NA |
19 |
6.5 |
22 |
|||
Total |
31 | 3 (1–9) | 82 | 4 (1–12) | 46 | 4 (1–9) | 27 | 7 (2–15) | 186 |
*No. indicates no. participants. Ct, cycle threshold; NA, not applicable. †Unknown for 9 participants. ‡Unknown for 16 participants. §Unknown for 12 participants. ¶Unknown for 9 participants.
Page created: March 16, 2021
Page updated: April 20, 2021
Page reviewed: April 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.